Corpus ID: 1764145

The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes.

@article{Auchampach1991TheNK,
  title={The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes.},
  author={J. Auchampach and M. Maruyama and I. Cavero and G. Gross},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1991},
  volume={259 3},
  pages={
          961-7
        }
}
The objective of the present study was to determine the effect of a novel K+ channel opener, Aprikalim (RP 52891; [trans-(-)-N-methyl-2-(3-pyridyl)-2-tetrahydrothio-pyran carbothiamide-1-oxide]), on myocardial infarct size in barbital-anesthetized dogs subjected to 90 min of left circumflex coronary artery occlusion followed by 5 hr of reperfusion. To determine if RP 52891 is mediating its effects by opening adenosine triphosphate regulated potassium channels (KATP), glibenclamide, a KATP… Expand
In swine myocardium, the infarct size reduction induced by U-89232 is glibenclamide sensitive: evidence that U-89232 is a cardioselective opener of ATP-sensitive potassium channels.
TLDR
At least in a pig model, U-89232 appears to be a cardioselective KATP channel opener, because in the absence of hemodynamic alterations, it exhibits a profound cardioprotective effect, which is fully reversible by blocking KatP channels. Expand
The myocardial lesions produced by the potassium channel opener aprikalim in monkeys and rats are prevented by blockade of cardiac beta-adrenoceptors.
  • V. Belin, T. Hodge, +5 authors I. Cavero
  • Medicine
  • Fundamental and applied toxicology : official journal of the Society of Toxicology
  • 1996
TLDR
In monkeys, aprikalim produced a marked and long-lasting decrease in aortic blood pressure, accompanied by an even more prolonged tachycardia, the first time that such adverse effects are reported for a vasodilator in monkeys. Expand
Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs.
TLDR
The results of the present study clearly reveal that a small dose of bimakalim mediates its cardioprotective effects by accelerating the rate of myocyte action potential shortening during early ischemia, and a large dose (0.1 or 0.1-microgram/min) did not significantly affect the ischemic-related shortening of the action potential during the initial 5 minutes of occlusion. Expand
Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels.
TLDR
Results indicate that Y-26763 protects the canine myocardium from reversible ischemia/reperfusion injury, probably through activation of myocardial KATP channels which appear to be involved in affording protection during the ischemic insult and not at the reperfusion. Expand
Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.
TLDR
The results of this study suggest that the cardioprotective effects of ATP-sensitive potassium channel openers are not dependent on adenosine A1 receptor activation in rat or dog models of ischemia. Expand
Reduction by ATP-Sensitive Potassium Channel Opener, YM934, of Experimental Myocardial Infarct Size in Anesthetized Dogs
TLDR
Observations indicate that intracoronary YM934 is cardioprotective and that this effect is independent of alterations in regional myocardial blood flow. Expand
The effects of a newly synthesized ATP-sensitive potassium channel opener, MJ-355, on blood pressure and myocardial ischemia-reperfusion injury in rats.
TLDR
It is suggested that MJ-355 should be useful in the treatment of hypertension and/or acute myocardial infarction after its activation of K(ATP) channels. Expand
The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K(+) channel opener.
TLDR
It is suggested that (-)- MJ-451 has potential in the treatment of hypertension or acute myocardial infarction, and the cardioprotective effects of (-)-MJ-451 were virtually abolished by pretreatment with glibenclamide (4 mg/kg, i.v. bolus). Expand
Altered Control of Vascular Tone by Adenosine Triphosphate- Sensitive Potassium Channels in Rats With Cirrhosis
TLDR
In rats with cirrhosis, the glibenclamide-induced vasoconstriction indicates that a vasodilator tone due to K ATP channel opening existed under baseline conditions, and suggests that the control of vascular tone by K ATP channels is altered in Cirrhosis. Expand
Effect of JTV-506, a novel vasodilator, on experimental angina model in rats.
TLDR
JTV-506 exerts a potent protective effect on angina pectoris models to an extent similar to those of levcromakalim, nicorandil, and nifedipine, whereas its action on systemic blood pressure is different from that of other vasodilators, including reference potassium channel openers. Expand
...
1
2
3
4
5
...